Compare Stocks: DERM, FBIO, IVA, and COLL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COLL Collegium Pharmaceutical	$22.45 -1.4%	$28.39	$21.65 ▼ $50.79	$741.63M	0.72	922,293 shs	878,390 shs
DERM Journey Medical	$6.50 -10.3%	$7.04	$4.31 ▼ $9.56	$204.63M	1.09	137,545 shs	342,313 shs
FBIO Fortress Biotech	$2.34 -4.5%	$2.86	$2.18 ▼ $4.53	$81.71M	1.19	281,795 shs	331,771 shs
IVA Inventiva	$3.45 -5.5%	$4.47	$3.35 ▼ $7.98	$758.13M	0.71	1.35 million shs	2.13 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COLL Collegium Pharmaceutical	-1.45%	+1.17%	-17.92%	-35.56%	-35.67%
DERM Journey Medical	-10.34%	-10.84%	-17.83%	+4.50%	-13.45%
FBIO Fortress Biotech	-4.49%	-4.88%	-20.14%	-22.52%	-35.89%
IVA Inventiva	-5.48%	-8.97%	-26.60%	-1.43%	-39.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COLL Collegium Pharmaceutical	$22.45 -1.4%	$28.39	$21.65 ▼ $50.79	$741.63M	0.72	922,293 shs	878,390 shs
DERM Journey Medical	$6.50 -10.3%	$7.04	$4.31 ▼ $9.56	$204.63M	1.09	137,545 shs	342,313 shs
FBIO Fortress Biotech	$2.34 -4.5%	$2.86	$2.18 ▼ $4.53	$81.71M	1.19	281,795 shs	331,771 shs
IVA Inventiva	$3.45 -5.5%	$4.47	$3.35 ▼ $7.98	$758.13M	0.71	1.35 million shs	2.13 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COLL Collegium Pharmaceutical	-1.45%	+1.17%	-17.92%	-35.56%	-35.67%
DERM Journey Medical	-10.34%	-10.84%	-17.83%	+4.50%	-13.45%
FBIO Fortress Biotech	-4.49%	-4.88%	-20.14%	-22.52%	-35.89%
IVA Inventiva	-5.48%	-8.97%	-26.60%	-1.43%	-39.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COLL Collegium Pharmaceutical	2.56	Moderate Buy	$48.71	116.99% Upside
DERM Journey Medical	2.25	Hold	$14.00	115.38% Upside
FBIO Fortress Biotech	2.25	Hold	$17.00	626.50% Upside
IVA Inventiva	3.09	Buy	$15.75	356.52% Upside

Current Analyst Ratings Breakdown

Latest DERM, FBIO, IVA, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	COLL Collegium Pharmaceutical	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
9/16/2026	IVA Inventiva	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/15/2026	IVA Inventiva	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $14.00
9/9/2026	COLL Collegium Pharmaceutical	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
9/9/2026	COLL Collegium Pharmaceutical	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$58.00 ➝ $49.00
9/9/2026	COLL Collegium Pharmaceutical	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$58.00 ➝ $49.00
9/9/2026	COLL Collegium Pharmaceutical	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
9/4/2026	COLL Collegium Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
8/19/2026	COLL Collegium Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$56.00 ➝ $48.00
8/14/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/13/2026	DERM Journey Medical	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00 ➝ $15.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COLL Collegium Pharmaceutical	$808.21M	0.90	$14.97 per share	1.50	$9.54 per share	2.35
DERM Journey Medical	$61.86M	2.97	N/A	N/A	$0.96 per share	6.77
FBIO Fortress Biotech	$63.26M	1.23	N/A	N/A	$2.00 per share	1.17
IVA Inventiva	$4.48M	159.85	N/A	N/A	($0.22) per share	-15.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COLL Collegium Pharmaceutical	$62.87M	$1.24	18.10	5.03	N/A	5.93%	91.43%	15.57%	11/5/2026 (Estimated)
DERM Journey Medical	-$11.43M	-$0.22	N/A	7.22	N/A	-8.95%	-20.23%	-6.60%	11/11/2026 (Estimated)
FBIO Fortress Biotech	$6.82M	$2.64	0.89	N/A	N/A	163.32%	83.47%	42.98%	11/16/2026 (Estimated)
IVA Inventiva	-$400.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/25/2026 (Estimated)

Latest DERM, FBIO, IVA, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2026	Q2 2026	IVA Inventiva	-$0.20	N/A	N/A	N/A	$6.35 million	N/A
8/13/2026	Q2 2026	FBIO Fortress Biotech	-$0.20	-$0.08	+$0.12	-$0.08	$18.30 million	$18.72 million
8/12/2026	Q2 2026	DERM Journey Medical	-$0.0225	-$0.01	+$0.0125	-$0.01	$18.36 million	$18.51 million
8/6/2026	Q2 2026	COLL Collegium Pharmaceutical	$1.72	$1.92	+$0.20	-$0.46	$199.63 million	$199.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COLL Collegium Pharmaceutical	3.32	1.03	0.84
DERM Journey Medical	0.64	1.59	1.41
FBIO Fortress Biotech	0.17	3.96	3.83
IVA Inventiva	N/A	3.16	3.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COLL Collegium Pharmaceutical	N/A
DERM Journey Medical	7.25%
FBIO Fortress Biotech	96.51%
IVA Inventiva	19.06%

Insider Ownership

Company	Insider Ownership
COLL Collegium Pharmaceutical	1.85%
DERM Journey Medical	14.53%
FBIO Fortress Biotech	28.50%
IVA Inventiva	32.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COLL Collegium Pharmaceutical	423	32.56 million	31.95 million	Optionable
DERM Journey Medical	58	28.22 million	24.12 million	N/A
FBIO Fortress Biotech	78	33.35 million	23.85 million	Optionable
IVA Inventiva	73	207.71 million	141.24 million	Not Optionable

DERM, FBIO, IVA, and COLL Headlines

Recent News About These Companies

Inventiva (NASDAQ:IVA) Shares Down 4.9% - What's Next?

September 21 at 11:59 AM | marketbeat.com

Delhi HC restrains Inventiva from publishing further defamatory articles against Terra Invest founder Krishan Rattan

September 21 at 8:30 AM | msn.com

Inventiva (IVA) Projected to Post Quarterly Earnings on Friday

September 18, 2026 | americanbankingnews.com

Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume - Should You Buy?

September 16, 2026 | marketbeat.com

Guggenheim Sticks to Its Buy Rating for Inventiva (IVA)

September 16, 2026 | theglobeandmail.com

Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

Inventiva To Present Lanifibranor Data Ahead Of Q4 NATiV3 Readout

September 10, 2026 | rttnews.com

Inventiva to Present Multiple Abstracts at Paris MASH 2026

September 8, 2026 | finance.yahoo.com

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Average Recommendation of "Buy" from Brokerages

September 6, 2026 | marketbeat.com

Inventiva (NASDAQ:IVA) Shares Gap Down - Here's Why

September 4, 2026 | marketbeat.com

Inventiva Reports Final Patient Visit In Phase 3 NATiV3 Study For Lanifibranor; Topline Data In Q4

September 3, 2026 | rttnews.com

Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH

September 2, 2026 | markets.businessinsider.com

Inventiva (NASDAQ:IVA) Shares Gap Up - What's Next?

September 2, 2026 | marketbeat.com

Inventiva names Chris Benecchi as COO ahead of pivotal lanifibranor readout

September 2, 2026 | thepharmaletter.comT

Inventiva Names Chris Benecchi As COO Ahead Of Lanifibranor's Phase 3 Readout

August 31, 2026 | rttnews.com

Chris Benecchi Named Inventiva’s New Chief Operating Officer

August 31, 2026 | finance.yahoo.com

INVENTIVA: Inventiva Appoints Chris Benecchi as Chief Operating Officer

August 31, 2026 | finanznachrichten.de

Inventiva names Chris Benecchi as COO

August 31, 2026 | msn.com

Inventiva Appoints Chris Benecchi as Chief Operating Officer

August 31, 2026 | finance.yahoo.com

Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives

August 5, 2026 | seekingalpha.com

Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹

July 30, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DERM, FBIO, IVA, and COLL Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

$22.45 -0.33 (-1.45%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$22.48 +0.03 (+0.13%)

As of 08:17 AM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Journey Medical NASDAQ:DERM

$6.50 -0.75 (-10.34%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$6.51 +0.01 (+0.22%)

As of 08:43 AM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Fortress Biotech NASDAQ:FBIO

$2.34 -0.11 (-4.49%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.34 0.00 (0.00%)

As of 09:11 AM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Inventiva NASDAQ:IVA

$3.45 -0.20 (-5.48%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.36 -0.09 (-2.58%)

As of 09:15 AM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DERM, FBIO, IVA, and COLL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DERM, FBIO, IVA, and COLL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DERM, FBIO, IVA, and COLL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DERM, FBIO, IVA, and COLL Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

Journey Medical NASDAQ:DERM

Fortress Biotech NASDAQ:FBIO

Inventiva NASDAQ:IVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DERM, FBIO, IVA, and COLL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DERM, FBIO, IVA, and COLL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DERM, FBIO, IVA, and COLL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DERM, FBIO, IVA, and COLL Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

Journey Medical NASDAQ:DERM

Fortress Biotech NASDAQ:FBIO

Inventiva NASDAQ:IVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools